Sign in
WithdrawnPhase 2

18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy

Key facts

Who runs it
UNC Lineberger Comprehensive Cancer Center
Trial code
Status
Withdrawn
Phase
Phase 2
Started
15 Feb 2024
Expected to end
Dec 2027
Type of study
Interventional
Treatments tested
  • 18F-fluorofuranylnorprogesterone PET / MRI
Record updated
14 October 2025
Why it stopped
Drug cannot be produced and scanner down.

Who can take part

Age
18 years and older
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Female age 18 or older
  • Histologically confirmed CAH or Grade 1 EC
  • No prior surgical or hormonal treatment for CAH or Grade 1 EC
  • Planned treatment with levonorgestrel-releasing intrauterine device (LR-IUD) for CAH or grade 1 EC

Who cannot take part

  • Prior hormone treatment for breast cancer
  • Known hypersensitivity to gadolinium or FFNP or to any component of gadolinium or FFNP refractory to standard medications (antihistamines, steroids)
  • Impaired kidney function (serum creatinine level > 1.8 mg/dl or a glomerular filtration rate < 60 as approximated using serum creatinine levels) unless anuric and on dialysis
  • Inability to complete PET/MR scans due to severe claustrophobia
  • Institutionalized subject (prisoner or nursing home subject)
  • Implanted metallic devices, parts, vascular clips, or other foreign bodies
  • Any woman who is pregnant or has reason to believe she is pregnant (the possibility of pregnancy has to be excluded by negative urine (β-HCG) results, obtained within 24 hours before FFNP administration, or on the basis of patient history)

About the trial

What the trial wants to find out

Purpose: The purpose of this study is to evaluate FFNP PET/MRI's utility for predicting response to Levonorgestrel-releasing Intrauterine Device (LR-IUD) hormonal therapy for Complex Atypical hyperplasia (CAH) and Endometrial Cancer (EC).

Read full original descriptionShow less

Participants: Eight women with histologically confirmed CAH or Grade 1 EC who have planned treatment with LR-IUD will be recruited..

Procedures (methods): The is a prospective, single arm, pilot study of 8 participants who will receive one FFNP PET/MRI scan. Medical records will be followed for 6 months.

The group in the trial

  • 18F-fluorofuranylnorprogesterone PET / MRITreatment being tested

    All enrolled subjects will receive the tracer and then have a PET/MRI scan.

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
18-fluorofuranylnorprogesterone (FFNP) Positron Emission Tomography-Magnetic Resonance Imaging (PET/MRI) as a Potential Biomarker of Response to Progesterone Therapy in Complex Atypical Hyperplasia (CAH) and Grade 1 Endometrial Cancer (EC)
Record updated
14 October 2025